Back to News
Market Impact: 0.2
Ferrer and Prilenia Announce Authorization for EU Initiation of Confirmatory PRECISE-HD Study of Pridopidine in Huntington's Disease
Source: Business Wire
Healthcare & Biotech
Ferrer and Prilenia announced authorization to initiate the confirmatory PRECISE-HD study of pridopidine in Huntington's disease in the EU. The headline provides no trial results, enrollment figures, timing, or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
More News
- Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
- Moderna shares plunge after leak of partial cancer vaccine data
- Moderna's stock tumbles after reported leak of data for cancer vaccine
- Palmer Luckey teams with dire wolf billionaire Ben Lamm to launch $200 million Warhound, unleashing genetically engineered clone dogs of war
- Zai Lab raises $250 million in private placement financing
- Why Moderna stock plunged despite positive cancer vaccine trail results?
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Hebbia Alternatives: A Workflow-Based Buyer’s Guide
- 2026 Global Markets Outlook: Asset Allocation After the Great Disconnect